WRITER'S DIRECT DIAL: (832) 886-5833

November 29, 2005

Temp. Ref.: 3999.002587





Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 29, 2005

Date

Shelley M.M. Fussey


RE: U.S. Application Serial No. 10/738,404; Entitled "Selective Anti-VEGF Antibody Prodrug Methods" (As Amended); by Thorpe and Brekken; U.T. Ref.: UTSD:1412-8 US; Peregrine Family: UTS06; Our Temp. Ref.: 3999.002587

Sir:

Enclosed for filing in the above-referenced patent application are:

- (1) Amendment; and Response to Restriction and Species Election Requirement Dated November 02, 2005;
- (2) Revocation of Power of Attorney; Election Under 37 C.F.R. §§ 3.71 and 3.73 and New Power of Attorney; and Change of Correspondence Address (unexecuted);
- (3) Supplemental Information Disclosure Statement;
- (4) PTO 1449 (C169 and C170);
- (5) Copies of References C169 and C170; and
- (6) A return postcard listing all these materials.

No fees are believed to be due in connection with these documents. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002587.





Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted PEREGRINE PHARMACEUTICALS, INC. CUSTOMER NO. 000052101

Shelley P.M. Fussey, Ph.D. Reg. No. 39,458 Agent for Applicants



November 29, 2005 Page 3

BethLynn Maxwell, Ph.D., J.D. bcc:

Ray Wheatley, M.S. (w/encl.)
Steven W. King, Ph.D. (via email)
Ramon Valencia, M.S. (w/encl., via email)

Philip E. Thorpe, Ph.D. (w/encl.)
Rolf A. Brekken, Ph.D. (w/encl.)